TrialBlood cancer journal2020

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.

Yiyun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.